A detailed history of Viewpoint Capital Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Viewpoint Capital Management LLC holds 30,576 shares of BMY stock, worth $1.75 Million. This represents 0.89% of its overall portfolio holdings.

Number of Shares
30,576
Previous 28,371 7.77%
Holding current value
$1.75 Million
Previous $1.18 Million 34.3%
% of portfolio
0.89%
Previous 0.73%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$39.66 - $51.75 $87,450 - $114,108
2,205 Added 7.77%
30,576 $1.58 Million
Q2 2024

Jul 30, 2024

BUY
$40.25 - $52.99 $1,006 - $1,324
25 Added 0.09%
28,371 $1.18 Million
Q1 2024

Apr 16, 2024

SELL
$47.98 - $54.4 $115,151 - $130,560
-2,400 Reduced 7.81%
28,346 $1.54 Million
Q4 2023

Jan 29, 2024

SELL
$48.48 - $57.85 $41,014 - $48,941
-846 Reduced 2.68%
30,746 $1.58 Million
Q3 2023

Oct 26, 2023

BUY
$57.89 - $64.73 $31,434 - $35,148
543 Added 1.75%
31,592 $1.83 Million
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $11,658 - $12,945
183 Added 0.59%
31,049 $1.99 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $45,471 - $51,574
-692 Reduced 2.19%
30,866 $2.14 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $173,459 - $205,400
-2,533 Reduced 7.43%
31,558 $2.27 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $282 - $166,896
-2,172 Reduced 5.99%
34,091 $2.57 Million
Q2 2022

Aug 11, 2022

BUY
$72.62 - $79.98 $13,652 - $15,036
188 Added 0.52%
36,263 $2.79 Million
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $25,637 - $30,741
-417 Reduced 1.14%
36,075 $2.64 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $1.96 Million - $2.28 Million
36,492 New
36,492 $2.28 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Viewpoint Capital Management LLC Portfolio

Follow Viewpoint Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Viewpoint Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Viewpoint Capital Management LLC with notifications on news.